- Home
- TDUP vs PALI Comparison
TDUP vs PALI Comparison
Compare TDUP & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | PALI |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.1M | 348.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TDUP | PALI |
|---|---|---|
| Price | $4.34 | $2.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.17 | ★ $11.29 |
| AVG Volume (30 Days) | 2.3M | ★ 4.3M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.36 | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $310,813,000.00 | $260,000.00 |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $10.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.53 | ★ 1500.39 |
| 52 Week Low | $3.08 | $0.55 |
| 52 Week High | $12.28 | $2.86 |
Technical Indicators
Market Signals| Indicator | TDUP | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 52.24 |
| Support Level | $4.33 | $1.57 |
| Resistance Level | $5.27 | $2.36 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 41.10 | 24.08 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.